Genetic factors
Sarasquete, et al, demonstrated that genetic perturbations, i.e. single nucleotide
polymorphisms (SNPs), in the cytochrome P450-2C gene (CYP2C8) gene were associated
with an increased risk for BRONJ among multiple myeloma patients treated with IV
bisphosphonates.